A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma

Overview of attention for article published in Frontiers in immunology, February 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter: 8 X users

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 21 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 36,395 followers.

RT @DenCell_Papers: A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKbeta-Matured, RNA-Loaded Dendritic C…

24 Feb 2022

Reply Repost Favourite

A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured,... https://t.co/34Fh0xgUZ8

22 Feb 2022

Reply Repost Favourite

A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKbeta-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma https://t.co/iiBc0DS9aw

22 Feb 2022

Reply Repost Favourite

A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma https://t.co/A2KFHTdyi9 https://t.co/S6nVv5Ehvn

21 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.